CpG-PEG Conjugates and their Immune Modulating Effects after Systemic Administration
- 198 Downloads
Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs were found to be able to target cells that express Toll-like receptor 9 to modulate innate and adaptive immune reactions. But their in vivo application in immunotherapy against cancer has not been successful. We attempted in this study to examine polyethylene-glycol (PEG) conjugated CpG ODNs and investigated their mechanism of immune modulation in anti-cancer therapy.
CpG-PEG conjugates with different PEG lengths were synthesized. In vitro activity as well as in vivo pharmacokinetics and pharmacodynamics properties were evaluated.
CpG-PEG20Ks were found to be able to persist longer in circulation and activate various downstream effector cells. After intravenous injection, they resulted in higher levels of IL-12p70 in the circulation and lower M-MDSC infiltrates in the tumor microenvironment. Such activities were different from those of CpG ODNs without PEGylation, suggesting different PK-PD profiles systemically and locally.
Our data support the development of CpG-PEGs as a new therapeutic agent that can be systemically administered to modulate immune responses and the microenvironment in tumor tissues.
Key WordsCpG-ODN PEG immune modulation systemic administation
PEG conjugated CpG ODNs
M type myeloid derived suppressor cells
Progression free survival
Toll-like receptor 9
CpG ODNs containing the sulfhydryl group
High performance liquid chromatography
Enzyme-linked immunosorbent assay
Bone-marrow-derived dendritic cells
A type I C-type lectin receptor that is expressed on various antigen presenting cell subsets
Quantitative- polymerase chain reaction
Enhanced permeability and retention
Triethylamine and acetic acid
- 2.Hirsh V, Paz-Ares L, Boyer M, Rosell R, Middleton G, Eberhardt WE, et al. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non–small-cell lung cancer. J Clin Oncol. 2011;29(19):2667–74.CrossRefPubMedGoogle Scholar
- 9.Raouane M, Desmaele D, Urbinati G, Massaad-Massade L, Couvreur P. Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjug Chem. 2012;Google Scholar
- 15.Jung S, Lee SH, Mok H, Chung HJ, Park TG. Gene silencing efficiency of siRNA-PEG conjugates: effect of PEGylation site and PEGmolecular weight. J Control Release. 2010:306–13.Google Scholar
- 16.Kim SH, Ji HJ, Lee SH, Kim SW, Park TG. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release. 2006:123–9.Google Scholar
- 20.Xu Z, Ramishetti S, Tseng YC, Guo S, Wang Y, Huang L. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release: official journal of the Controlled Release Society. 2013;172:259–65.CrossRefGoogle Scholar
- 23.Nierkens S, den Brok MH, Roelofsen T, Wagenaars JA, Figdor CG, Ruers TJ, et al. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS One. 2009;4(12)Google Scholar
- 27.Yi A-K, Krieg AM. CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of IκBα and IκBβ and sustained activation of nuclear factor-κB/c-Rel. J Immunol 1998;160:1240–1245.Google Scholar
- 30.Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol. 2012;188:000–0.Google Scholar